Jian Wang

Jian Wang’s practice focuses on cross-border mergers and acquisitions, capital markets transactions, corporate finance, investments and public company compliance matters.

Mr. Wang’s experience mainly includes advising:

Going-Private Acquisitions, Reorganizations and Other Public M&A

• as counsel to the issuer for: 58.com Inc. in its going-private acquisition; China Petroleum & Chemical Corporation in its pipeline assets disposal; China Petroleum & Chemical Corporation and Huaneng Power International Inc. in their voluntary delisting from NYSE and Rule 12h-6 deregistration under U.S. securities laws and CASI Pharmaceuticals, Inc. and China Automotive Systems, Inc. in their redomiciliation from Delaware to the Cayman Islands and the related registered exchange offering of ordinary shares
• as counsel to the special committee of the board for: Smart Share Global Limited, BEST Inc., O2Micro International Limited, Wanda Sports Group Company and Changyou.com Limited in their going-private acquisitions; and CASI Pharmaceuticals, Inc. in its China business disposal
• as consortium counsel in consortiums’ going-private acquisitions of Genetron Holdings Limited, Fuling Global Inc. and JA Solar Holdings Co., Ltd.
• as sole buyer counsel in buyers’ going-private acquisitions of Sina Corporation and Jumei International Holding Limited
• as counsel to the consortium member in its going-private acquisition of Cloopen Group Holding Limited

Private Financing

• CASI Pharmaceuticals, Inc. in its US$15 million PIPE transaction and US$20 million convertible notes financing
• 9F Inc. in its US$60 million PIPE transaction
• Qifu Technology, Inc. in its US$200 million pre-IPO financing
• NIO Inc. in its US$1 billion pre-IPO financing

Capital Markets

• Hi-Think Technology International Limited and Beijing Yuanxin Technology Group Co., Ltd. in their listing application with HKEX
• Nomura Securities International, Inc. as sole underwriter in the US$200 million IPO and listing on NYSE of Generation Asia I Acquisition Limited
• Sinopec Group in its multiple Rule 144A/Regu-lation S offerings of U.S. dollar-denominated senior notes
• 9F Inc. in its US$85 million IPO and listing on Nasdaq
• Qifu Technology, Inc. in US$51 million IPO and listing on Nasdaq, and the US$96 million offering by its shareholders
• U.S.-listed companies, including CASI Pharmaceuticals, Inc. and 9F Inc., as well as China Petroleum & Chemical Corporation, Huaneng Power International Inc. and JA Solar Holdings Co., Ltd. on their regulatory compliance and preparation of filings under Securities Exchange Act of 1934